Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients

Aliment Pharmacol Ther. 2019 Apr;49(8):1105-1106. doi: 10.1111/apt.15150.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antiviral Agents*
  • Guanine / analogs & derivatives
  • Hepatitis B virus
  • Hepatitis B, Chronic*
  • Humans
  • Recurrence
  • Tenofovir

Substances

  • Antiviral Agents
  • entecavir
  • Guanine
  • Tenofovir